Elanco Receives EC’s Approval for its Pending Acquisition of Bayer Animal Health

Shots:

• The EC has granted approval of Elanco’s pending acquisition of Bayer’s animal health business. The company continues to progress toward a mid-year closing, anticipated Aug 03, 2020
• The EC’s approval follows the divestiture of global rights for Osurnia to treat otitis externa in dogs, WW rights of Vecoxa to prevent & treat coccidiosis in calves and lambs being sold to Merck Animal Health and the European Economic Area and UK rights to the Drontal and Profende product families with related pipeline assets being sold to Vetoquinol SA
• In addition to EC approval, Elanco has received antitrust clearance for the transaction in China, Colombia, South Africa, Turkey, Ukraine, Vietnam, and provisional clearance in Brazil

Click here ­to­ read full press release/ article | Ref: Elanco | Image: Livemint